首页> 外文期刊>Annals of hematology >Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: Single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL)
【24h】

Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: Single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL)

机译:鼻外型NK / T细胞淋巴瘤(ENKL),I-IIE期的治疗效果的回顾性分析:早期局部鼻外结节NK / T细胞淋巴瘤(ENKL)联合治疗的单一机构经验

获取原文
获取原文并翻译 | 示例
       

摘要

Extranodal natural killer/T-cell lymphoma (ENKL) is a very aggressive disease frequently involving the nasal cavity and upper aerodigestive tract. We retrospectively reviewed the treatment outcomes and treatment-associated complications of the patients with stage I-II early localized ENKL. A total of 24 patients were included. All patients were treated with combined chemoradiotherapy. Three, sixteen, and five patients were initially treated with radiation therapy, chemotherapy, and surgical procedures, respectively. Nine patients underwent hematopoietic stem cell transplantation (HSCT), and four patients administered immunotherapy with pegylated-interferon alpha. The mean observation time was 71.6 months (range, 29.7-183.6 months). Twenty patients achieved complete remission; thus, the overall response rate was 83.3 %. The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 70.3 % and 62.2 %, respectively. In univariate analysis, HSCT was a significant prognostic indicator for OS and RFS. By combining HSCT, the 5-year OS and RFS rates were 100.0 % vs. 52.5 % (p = 0.018) and 88.9 % vs. 45.7 % (p = 0.045), respectively. Also, absence of B symptoms was a good prognostic factor for RFS, the 5-year RFS rate, 75.0 % vs. 25.0 % (p = 0.010), and B symptoms were significant for RFS in multivariate analysis (odds ratio = 7.4, confidence interval = 1.6~34.1, p = 0.011). However, a total of four cases of grade 3 toxicities were reported. Radiation dose range (??4,500 vs. >4,500 cGy) was significantly correlated with late complications, as more severe complications occurred more frequently with a radiation dose >4,500 cGy (p = 0.026, in multivariate analysis). For more efficient treatment of ENKL, chemotherapy, HSCT, and/or immunotherapy can be combined with radiation therapy to prolong long-term survival and achieve good local control. Also, lower radiation dose could be administered to avoid severe late complications. ? 2012 Springer-Verlag Berlin Heidelberg.
机译:结外自然杀伤/ T细胞淋巴瘤(ENKL)是一种非常侵袭性的疾病,经常累及鼻腔和上消化道。我们回顾性地回顾了I-II期早期局限性ENKL患者的治疗结果和与治疗相关的并发症。总共包括24名患者。所有患者均接受联合放化疗。最初分别对3例,16例和5例患者进行了放射疗法,化学疗法和外科手术治疗。 9例患者接受了造血干细胞移植(HSCT),4例患者接受了聚乙二醇干扰素α的免疫治疗。平均观察时间为71.6个月(范围29.7-183.6个月)。 20例患者完全缓解。因此,总答复率为83.3%。 5年总生存率(OS)和无复发生存率(RFS)分别为70.3%和62.2%。在单变量分析中,HSCT是OS和RFS的重要预后指标。通过结合HSCT,五年OS和RFS发生率分别为100.0%对52.5%(p = 0.018)和88.9%对45.7%(p = 0.045)。此外,无B症状是RFS的良好预后因素,5年RFS发生率分别为75.0%和25.0%(p = 0.010),在多变量分析中B症状对于RFS显着(赔率= 7.4,置信度间隔= 1.6〜34.1,p = 0.011)。但是,总共报告了4例3级毒性。放射剂量范围(?4,500 vs.> 4,500 cGy)与晚期并发症显着相关,因为放射剂量> 4,500 cGy时发生更严重的并发症的频率更高(在多变量分析中,p = 0.026)。为了更有效地治疗ENKL,可以将化学疗法,HSCT和/或免疫疗法与放射疗法结合使用,以延长长期生存期并实现良好的局部控制。而且,可以给予较低的辐射剂量以避免严重的后期并发症。 ? 2012年施普林格出版社柏林海德堡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号